SK Biopharmaceuticals has declared its ambition to leap forward as a "big biotech" company, unveiling a mid- to long-term R&D (research and development) roadmap centered on next-generation pipelines and platform technologies that go beyond the success of its flagship product, cenobamate.

SK Biopharmaceuticals Unveils CNS and RPT Strategy...Poised to Become a Big Biotech View original image

On February 6, SK Biopharmaceuticals presented its R&D strategy during an R&D session held alongside its earnings announcement, outlining a research and development framework built on two main pillars: central nervous system (CNS) therapies and radiopharmaceutical therapies (RPT). The company plans to maximize its corporate value by concentrating the substantial cash flow secured through cenobamate on future growth drivers.


In this session, Executive Vice President and Chief Technology Officer (CTO) Hwang Sunkwan emphasized the company’s strategy for developing disease-modifying therapies (DMTs) in the CNS field. The goal is to develop innovative new drugs that not only alleviate symptoms but also slow or even reverse the progression of intractable diseases such as Parkinson’s disease. To this end, the company plans to introduce a biomarker-based precision medicine approach and build a pipeline with a high probability of success.


In the RPT segment presented by Center Head Shin Yongje, the company shared plans to secure a proprietary chelator platform, along with the core competitiveness of both its internally developed and in-licensed pipelines. Since announcing its entry into RPT in 2023, SK Biopharmaceuticals has steadily expanded its pipeline, and more recently has been focusing on strengthening its internal platform capabilities to continuously generate new drug candidates, as well as diversifying its stable supply chain for radioisotopes (RI).



A representative of SK Biopharmaceuticals stated, "We are the only company in Korea with experience in completing the entire process from new drug discovery to FDA approval and commercial launch in the United States," adding, "We will continue to create successful models for new drug development in Korea by communicating the progress of our next-generation platform technologies transparently with the market."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing